Nassima Bekaddour
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nassima Bekaddour has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Jean-Philippe Herbeuval
Centre National de la Recherche Scientifique (CNRS) Unité Mixte de Recherche (UMR) 8601, Université Paris Cité, Paris, France
7 shared publications - Sébastien Nisole
IRIM, Univ. Montpellier, CNRS, Montpellier, France
4 shared publications Anne-Sophie Korganow
Université de Strasbourg, Institut National de la Santé et de la Recherche Médicale (INSERM), Unité Mixte de Recherche (UMR) S1109, Institut Thématique Interdisciplinaire (ITI) de Médecine de Précision de Strasbourg, Transplantation Excellence Nouvelle Génération (Transplantex NG), Fédération Hospitalo-Universitaire OMICs for Care (OMICARE), Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
3 shared publicationsBrigitte Bader-Meunier
10 Paediatric Haematology-Immunology and Rheumatology Department, Centre de référence des rhumatismes inflammatoires et maladies auto-immunes systémiques rares de l'enfant (RAISE) Reference Centre for Rare Diseases, Hôpital Universitaire Necker, Assistance Publique-Hôpitaux de Paris, Paris, France
3 shared publications- Darragh Duffy
Translational Immunology Unit, Institut Pasteur, Université Paris Cité, Paris, France
3 shared publications - Mathieu Paul Rodero
Chimie & Biologie, Modélisation et Immunologie pour la Thérapie (CBMIT), Université Paris Descartes, CNRS, UMR8601
3 shared publications
Latest Publications
- 4 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Etude des effets immunorégulateurs des ligands du récepteur à chimiokine CXCR4, avec application thérapeutique pour les maladies auto-immunes et inflammatoires
Les interférons (IFN) sont des cytokines qui jouent un rôle central dans la réponse immunitaire aux agents infectieux, notamment dans la lutte contre les virus, et qui contribuent à prévenir le développement de tumeurs. Une production aberrante d'IFN de manière chronique ou aiguë est néfaste pour l'organisme car induit des lésions plus ou moins importantes. Le lupus, maladie qui touche près de cinq millions de personnes dans le monde fait partie de cette catégorie de pathologie. Il a récemment été identifié qu'un récépteur présente à la surface des cellules immunitaires, appelée CXCR4 est capable de réguler la production d'IFN en présence de virus. Cette régulation se fait par l'intermédiaire de composés aminés, naturels ou synthétiques, qui se fixent sur la poche mineure de CXCR4. L'IT1t ainsi que l'analogue de l'histamine : le clobenpropit (CB) sont capables de se fixer au niveau de cette poche, induisant par conséquence une activité anti-IFN. L'IT1t a été testé in vivo dans un modèle de lupus chez la souris : l'inflammation systémique et la progression de la maladie ont été considérablement réduites. La molécule s'est aussi avérée efficace sur des cellules de patients atteints de lupus, confirmant ainsi l'immense potentiel de cette nouvelle option thérapeutique dans le traitement de cette maladie. L'objectif de mon travail de thèse a été dans un premier temps de mieux caractériser les effets immunorégulateurs de l'IT1t et du CB. Nous avons ainsi pu identifier que ces composés exercent des effets anti-inflammatoires à large spectre en inhibant notamment la production de cytokines pro-inflammatoires tels que le TNFa, l'IL6 et IL1b par des monocytes activés. Ces cytokines inflammatoires sont incriminées dans un grand nombre de maladies inflammatoires tel que la polyarthrite rhumatoïde qui touche plus de 23 millions de personnes. Le CB a ainsi été testé en ex vivo sur des cellules immunitaires de patients atteints d'arthrites, ce qui a permis de réduire drastiquement la production de cytokines pro-inflammatoires. Nous avons démontré que l'effet anti-inflammatoire du CB sur la production cytokines inflammatoires est strictement dépendant de CXCR4. Enfin, l'IT1t a été testé in vivo dans un modèle de souris arthritique : l'inflammation systémique et la progression de la maladie ont été considérablement réduites. Mon deuxième objectif a été d'identifier de nouveaux composés avec des effets anti-inflammatoires capables de se fixer sur la poche mineure de CXCR4. Deux composés ont ainsi pu être identifiés avec une meilleure activité anti-inflammatoire que le CB et l'IT1t. Enfin, la dernière partie de mes travaux consiste à décortiquer le mécanisme d'action induit par les ligands de la poche mineure de CXCR4 qui aboutit aux effets anti-inflammatoires et anti-IFN observés.
- 4 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Etude des effets immunorégulateurs des ligands du récepteur à chimiokine CXCR4, avec application thérapeutique pour les maladies auto-immunes et inflammatoires
Les interférons (IFN) sont des cytokines qui jouent un rôle central dans la réponse immunitaire aux agents infectieux, notamment dans la lutte contre les virus, et qui contribuent à prévenir le développement de tumeurs. Une production aberrante d'IFN de manière chronique ou aiguë est néfaste pour l'organisme car induit des lésions plus ou moins importantes. Le lupus, maladie qui touche près de cinq millions de personnes dans le monde fait partie de cette catégorie de pathologie. Il a récemment été identifié qu'un récépteur présente à la surface des cellules immunitaires, appelée CXCR4 est capable de réguler la production d'IFN en présence de virus. Cette régulation se fait par l'intermédiaire de composés aminés, naturels ou synthétiques, qui se fixent sur la poche mineure de CXCR4. L'IT1t ainsi que l'analogue de l'histamine : le clobenpropit (CB) sont capables de se fixer au niveau de cette poche, induisant par conséquence une activité anti-IFN. L'IT1t a été testé in vivo dans un modèle de lupus chez la souris : l'inflammation systémique et la progression de la maladie ont été considérablement réduites. La molécule s'est aussi avérée efficace sur des cellules de patients atteints de lupus, confirmant ainsi l'immense potentiel de cette nouvelle option thérapeutique dans le traitement de cette maladie. L'objectif de mon travail de thèse a été dans un premier temps de mieux caractériser les effets immunorégulateurs de l'IT1t et du CB. Nous avons ainsi pu identifier que ces composés exercent des effets anti-inflammatoires à large spectre en inhibant notamment la production de cytokines pro-inflammatoires tels que le TNFa, l'IL6 et IL1b par des monocytes activés. Ces cytokines inflammatoires sont incriminées dans un grand nombre de maladies inflammatoires tel que la polyarthrite rhumatoïde qui touche plus de 23 millions de personnes. Le CB a ainsi été testé en ex vivo sur des cellules immunitaires de patients atteints d'arthrites, ce qui a permis de réduire drastiquement la production de cytokines pro-inflammatoires. Nous avons démontré que l'effet anti-inflammatoire du CB sur la production cytokines inflammatoires est strictement dépendant de CXCR4. Enfin, l'IT1t a été testé in vivo dans un modèle de souris arthritique : l'inflammation systémique et la progression de la maladie ont été considérablement réduites. Mon deuxième objectif a été d'identifier de nouveaux composés avec des effets anti-inflammatoires capables de se fixer sur la poche mineure de CXCR4. Deux composés ont ainsi pu être identifiés avec une meilleure activité anti-inflammatoire que le CB et l'IT1t. Enfin, la dernière partie de mes travaux consiste à décortiquer le mécanisme d'action induit par les ligands de la poche mineure de CXCR4 qui aboutit aux effets anti-inflammatoires et anti-IFN observés.
- Open Access
- 16 December 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1490593
The histamine analogue clobenpropit modulates IRF7 phosphorylation and interferon production by targeting CXCR4 in systemic lupus erythematosus models
Introduction: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by an overactive immune response, particularly involving excessive production of type I interferons. This overproduction is driven by the phosphorylation of IRF7, a crucial factor in interferon gene activation. Current treatments for SLE are often not very effective and can have serious side effects.Methods: Our study introduces clobenpropit, a histamine analogue, as a potential new therapy targeting the CXCR4 receptor to reduce IRF7 phosphorylation and subsequent interferon production. We employed various laboratory techniques to investigate how clobenpropit interacts with CXCR4 and its effects on immune cells from healthy individuals and SLE patients.Results: Clobenpropit binds effectively to CXCR4, significantly inhibiting IRF7 phosphorylation and reducing interferon production. Additionally, clobenpropit lowered levels of pro-inflammatory cytokines in a mouse model of lupus, demonstrating efficacy comparable to the standard treatment, prednisolone.Discussion: These results suggest that clobenpropit could be a promising new treatment for SLE, offering a targeted approach with potential advantages over current therapies.
- 16 December 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1490593
Open AccessThe histamine analogue clobenpropit modulates IRF7 phosphorylation and interferon production by targeting CXCR4 in systemic lupus erythematosus models
Introduction: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by an overactive immune response, particularly involving excessive production of type I interferons. This overproduction is driven by the phosphorylation of IRF7, a crucial factor in interferon gene activation. Current treatments for SLE are often not very effective and can have serious side effects.Methods: Our study introduces clobenpropit, a histamine analogue, as a potential new therapy targeting the CXCR4 receptor to reduce IRF7 phosphorylation and subsequent interferon production. We employed various laboratory techniques to investigate how clobenpropit interacts with CXCR4 and its effects on immune cells from healthy individuals and SLE patients.Results: Clobenpropit binds effectively to CXCR4, significantly inhibiting IRF7 phosphorylation and reducing interferon production. Additionally, clobenpropit lowered levels of pro-inflammatory cytokines in a mouse model of lupus, demonstrating efficacy comparable to the standard treatment, prednisolone.Discussion: These results suggest that clobenpropit could be a promising new treatment for SLE, offering a targeted approach with potential advantages over current therapies.
- Top Cited PapersOpen Access
Macrophages: Key Cellular Players in HIV Infection and Pathogenesis
Although cells of the myeloid lineages, including tissue macrophages and conventional dendritic cells, were rapidly recognized, in addition to CD4+ T lymphocytes, as target cells of HIV-1, their specific roles in the pathophysiology of infection were initially largely neglected. However, numerous studies performed over the past decade, both in vitro in cell culture systems and in vivo in monkey and humanized mouse animal models, led to growing evidence that macrophages play important direct and indirect roles as HIV-1 target cells and in pathogenesis. It has been recently proposed that macrophages are likely involved in all stages of HIV-1 pathogenesis, including virus transmission and dissemination, but above all, in viral persistence through the establishment, together with latently infected CD4+ T cells, of virus reservoirs in many host tissues, the major obstacle to virus eradication in people living with HIV. Infected macrophages are indeed found, very often as multinucleated giant cells expressing viral antigens, in almost all lymphoid and non-lymphoid tissues of HIV-1-infected patients, where they can probably persist for long period of time. In addition, macrophages also likely participate, directly as HIV-1 targets or indirectly as key regulators of innate immunity and inflammation, in the chronic inflammation and associated clinical disorders observed in people living with HIV, even in patients receiving effective antiretroviral therapy. The main objective of this review is therefore to summarize the recent findings, and also to revisit older data, regarding the critical functions of tissue macrophages in the pathophysiology of HIV-1 infection, both as major HIV-1-infected target cells likely found in almost all tissues, as well as regulators of innate immunity and inflammation during the different stages of HIV-1 pathogenesis.
Top Cited PapersOpen AccessMacrophages: Key Cellular Players in HIV Infection and Pathogenesis
Although cells of the myeloid lineages, including tissue macrophages and conventional dendritic cells, were rapidly recognized, in addition to CD4+ T lymphocytes, as target cells of HIV-1, their specific roles in the pathophysiology of infection were initially largely neglected. However, numerous studies performed over the past decade, both in vitro in cell culture systems and in vivo in monkey and humanized mouse animal models, led to growing evidence that macrophages play important direct and indirect roles as HIV-1 target cells and in pathogenesis. It has been recently proposed that macrophages are likely involved in all stages of HIV-1 pathogenesis, including virus transmission and dissemination, but above all, in viral persistence through the establishment, together with latently infected CD4+ T cells, of virus reservoirs in many host tissues, the major obstacle to virus eradication in people living with HIV. Infected macrophages are indeed found, very often as multinucleated giant cells expressing viral antigens, in almost all lymphoid and non-lymphoid tissues of HIV-1-infected patients, where they can probably persist for long period of time. In addition, macrophages also likely participate, directly as HIV-1 targets or indirectly as key regulators of innate immunity and inflammation, in the chronic inflammation and associated clinical disorders observed in people living with HIV, even in patients receiving effective antiretroviral therapy. The main objective of this review is therefore to summarize the recent findings, and also to revisit older data, regarding the critical functions of tissue macrophages in the pathophysiology of HIV-1 infection, both as major HIV-1-infected target cells likely found in almost all tissues, as well as regulators of innate immunity and inflammation during the different stages of HIV-1 pathogenesis.
- Open Access
- 26 September 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1178172
Targeting the chemokine receptor CXCR4 with histamine analog to reduce inflammation in juvenile arthritis
Introduction: Among immune cells, activated monocytes play a detrimental role in chronic and viral-induced inflammatory pathologies, particularly in Juvenile Idiopathic Arthritis (JIA), a childhood rheumatoid arthritis (RA) disease. The uncontrolled activation of monocytes and excessive production of inflammatory factors contribute to the damage of bone-cartilage joints. Despite the moderate beneficial effect of current therapies and clinical trials, there is still a need for alternative strategies targeting monocytes to treat RA.Methods: To explore such an alternative strategy, we investigated the effects of targeting the CXCR4 receptor using the histamine analog clobenpropit (CB). Monocytes were isolated from the blood and synovial fluids of JIA patients to assess CB's impact on their production of key inflammatory cytokines. Additionally, we administered daily intraperitoneal CB treatment to arthritic mice to evaluate its effects on circulating inflammatory cytokine levels, immune cell infiltrates, joints erosion, and bone resorption, as indicators of disease progression.Results: Our findings demonstrated that CXCR4 targeting with CB significantly inhibited the spontaneous and induced-production of key inflammatory cytokines by monocytes isolated from JIA patients. Furthermore, CB treatment in a mouse model of collagen-induce arthritis resulted in a significant decrease in circulating inflammatory cytokine levels, immune cell infiltrates, joints erosion, and bone resorption, leading to a reduction in disease progression.Discussion: In conclusion, targeting CXCR4 with the small amino compound CB shows promise as a therapeutic option for chronic and viral-induced inflammatory diseases, including RA. CB effectively regulated inflammatory cytokine production of monocytes, presenting a potential targeted approach with potential advantages over current therapies. These results warrant further research and clinical trials to explore the full therapeutic potential of targeting CXCR4 with CB-like molecules in the management of various inflammatory diseases.
- 26 September 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1178172
Open AccessTargeting the chemokine receptor CXCR4 with histamine analog to reduce inflammation in juvenile arthritis
Introduction: Among immune cells, activated monocytes play a detrimental role in chronic and viral-induced inflammatory pathologies, particularly in Juvenile Idiopathic Arthritis (JIA), a childhood rheumatoid arthritis (RA) disease. The uncontrolled activation of monocytes and excessive production of inflammatory factors contribute to the damage of bone-cartilage joints. Despite the moderate beneficial effect of current therapies and clinical trials, there is still a need for alternative strategies targeting monocytes to treat RA.Methods: To explore such an alternative strategy, we investigated the effects of targeting the CXCR4 receptor using the histamine analog clobenpropit (CB). Monocytes were isolated from the blood and synovial fluids of JIA patients to assess CB's impact on their production of key inflammatory cytokines. Additionally, we administered daily intraperitoneal CB treatment to arthritic mice to evaluate its effects on circulating inflammatory cytokine levels, immune cell infiltrates, joints erosion, and bone resorption, as indicators of disease progression.Results: Our findings demonstrated that CXCR4 targeting with CB significantly inhibited the spontaneous and induced-production of key inflammatory cytokines by monocytes isolated from JIA patients. Furthermore, CB treatment in a mouse model of collagen-induce arthritis resulted in a significant decrease in circulating inflammatory cytokine levels, immune cell infiltrates, joints erosion, and bone resorption, leading to a reduction in disease progression.Discussion: In conclusion, targeting CXCR4 with the small amino compound CB shows promise as a therapeutic option for chronic and viral-induced inflammatory diseases, including RA. CB effectively regulated inflammatory cytokine production of monocytes, presenting a potential targeted approach with potential advantages over current therapies. These results warrant further research and clinical trials to explore the full therapeutic potential of targeting CXCR4 with CB-like molecules in the management of various inflammatory diseases.
- Open Access
- 7 July 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (27) , eadf8251
Spermine and spermidine bind CXCR4 and inhibit CXCR4- but not CCR5-tropic HIV-1 infection
Semen is an important vector for sexual HIV-1 transmission. Although CXCR4-tropic (X4) HIV-1 may be present in semen, almost exclusively CCR5-tropic (R5) HIV-1 causes systemic infection after sexual intercourse. To identify factors that may limit sexual X4-HIV-1 transmission, we generated a seminal fluid–derived compound library and screened it for antiviral agents. We identified four adjacent fractions that blocked X4-HIV-1 but not R5-HIV-1 and found that they all contained spermine and spermidine, abundant polyamines in semen. We showed that spermine, which is present in semen at concentrations up to 14 mM, binds CXCR4 and selectively inhibits cell-free and cell-associated X4-HIV-1 infection of cell lines and primary target cells at micromolar concentrations. Our findings suggest that seminal spermine restricts sexual X4-HIV-1 transmission.
- 7 July 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (27) , eadf8251
Open AccessSpermine and spermidine bind CXCR4 and inhibit CXCR4- but not CCR5-tropic HIV-1 infection
Semen is an important vector for sexual HIV-1 transmission. Although CXCR4-tropic (X4) HIV-1 may be present in semen, almost exclusively CCR5-tropic (R5) HIV-1 causes systemic infection after sexual intercourse. To identify factors that may limit sexual X4-HIV-1 transmission, we generated a seminal fluid–derived compound library and screened it for antiviral agents. We identified four adjacent fractions that blocked X4-HIV-1 but not R5-HIV-1 and found that they all contained spermine and spermidine, abundant polyamines in semen. We showed that spermine, which is present in semen at concentrations up to 14 mM, binds CXCR4 and selectively inhibits cell-free and cell-associated X4-HIV-1 infection of cell lines and primary target cells at micromolar concentrations. Our findings suggest that seminal spermine restricts sexual X4-HIV-1 transmission.
- Open Access
Targeting the chemokine receptor CXCR4 with histamine analogue to reduce inflammation in juvenile arthritis: a proof of concept for COVID-19 therapeutic approach
Among immune cells, activated monocytes play a detrimental role in chronic and viral-induced inflammatory pathologies. The uncontrolled activation of monocytes and the subsequent excessive production of inflammatory factors damage bone-cartilage joints in Juvenile Idiopathic Arthritis (JIA), a childhood rheumatoid arthritis (RA) disease. Inflammatory monocytes also exert a critical role in the cytokine storm induced by SARS-CoV2 infection in severe COVID-19 patients. The moderate beneficial effect of current therapies and clinical trials highlights the need of alternative strategies targeting monocytes to treat RA and COVID-19 pathologies. Here, we show that targeting CXCR4 with small amino compound such as the histamine analogue clobenpropit (CB) inhibits spontaneous and induced-production of a set of key inflammatory cytokines by monocytes isolated from blood and synovial fluids of JIA patients. Moreover, daily intraperitoneal CB treatment of arthritic mice results in significant decrease in circulating inflammatory cytokine levels, immune cell infiltrates, joints erosion, and bone resorption leading to reduction of disease progression. Finally, we provide the prime evidence that the exposure of whole blood from hospitalized COVID-19 patients to CB significantly reduces levels of key cytokine-storm-associated factors including TNF-α, IL-6 and IL-1β. These overall data show that targeting CXCR4 with CB-like molecules may represent a promising therapeutic option for chronic and viral-induced inflammatory diseases.
Open AccessTargeting the chemokine receptor CXCR4 with histamine analogue to reduce inflammation in juvenile arthritis: a proof of concept for COVID-19 therapeutic approach
Among immune cells, activated monocytes play a detrimental role in chronic and viral-induced inflammatory pathologies. The uncontrolled activation of monocytes and the subsequent excessive production of inflammatory factors damage bone-cartilage joints in Juvenile Idiopathic Arthritis (JIA), a childhood rheumatoid arthritis (RA) disease. Inflammatory monocytes also exert a critical role in the cytokine storm induced by SARS-CoV2 infection in severe COVID-19 patients. The moderate beneficial effect of current therapies and clinical trials highlights the need of alternative strategies targeting monocytes to treat RA and COVID-19 pathologies. Here, we show that targeting CXCR4 with small amino compound such as the histamine analogue clobenpropit (CB) inhibits spontaneous and induced-production of a set of key inflammatory cytokines by monocytes isolated from blood and synovial fluids of JIA patients. Moreover, daily intraperitoneal CB treatment of arthritic mice results in significant decrease in circulating inflammatory cytokine levels, immune cell infiltrates, joints erosion, and bone resorption leading to reduction of disease progression. Finally, we provide the prime evidence that the exposure of whole blood from hospitalized COVID-19 patients to CB significantly reduces levels of key cytokine-storm-associated factors including TNF-α, IL-6 and IL-1β. These overall data show that targeting CXCR4 with CB-like molecules may represent a promising therapeutic option for chronic and viral-induced inflammatory diseases.
- Open Access
Differential levels of IFNα subtypes in autoimmunity and viral infection
Type I interferons are essential for host response to viral infections, while dysregulation of their response can result in autoinflammation or autoimmunity. Among IFNα (alpha) responses, 13 subtypes exist that signal through the same receptor, but have been reported to have different effector functions. However, the lack of available tools for discriminating these closely related subtypes, in particular at the protein level, has restricted the study of their differential roles in disease. We developed a digital ELISA with specificity and high sensitivity for the IFNα2 subtype. Application of this assay, in parallel with our previously described pan-IFNα assay, allowed us to study different IFNα protein responses following cellular stimulation and in diverse patient cohorts. We observed different ratios of IFNα protein responses between viral infection and autoimmune patients. This analysis also revealed a small percentage of autoimmune patients with high IFNα2 protein measurements but low pan-IFNα measurements. Correlation with an ISG score and functional activity showed that in this small sub group of patients, IFNα2 protein measurements did not reflect its biological activity. This unusual phenotype was partly explained by the presence of anti-IFNα auto-antibodies in a subset of autoimmune patients. This study reports ultrasensitive assays for the study of IFNα proteins in patient samples and highlights the insights that can be obtained from the use of multiple phenotypic readouts in translational and clinical studies.
Open AccessDifferential levels of IFNα subtypes in autoimmunity and viral infection
Type I interferons are essential for host response to viral infections, while dysregulation of their response can result in autoinflammation or autoimmunity. Among IFNα (alpha) responses, 13 subtypes exist that signal through the same receptor, but have been reported to have different effector functions. However, the lack of available tools for discriminating these closely related subtypes, in particular at the protein level, has restricted the study of their differential roles in disease. We developed a digital ELISA with specificity and high sensitivity for the IFNα2 subtype. Application of this assay, in parallel with our previously described pan-IFNα assay, allowed us to study different IFNα protein responses following cellular stimulation and in diverse patient cohorts. We observed different ratios of IFNα protein responses between viral infection and autoimmune patients. This analysis also revealed a small percentage of autoimmune patients with high IFNα2 protein measurements but low pan-IFNα measurements. Correlation with an ISG score and functional activity showed that in this small sub group of patients, IFNα2 protein measurements did not reflect its biological activity. This unusual phenotype was partly explained by the presence of anti-IFNα auto-antibodies in a subset of autoimmune patients. This study reports ultrasensitive assays for the study of IFNα proteins in patient samples and highlights the insights that can be obtained from the use of multiple phenotypic readouts in translational and clinical studies.
- Open Access
- 5 July 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 5 (7) , eaav9019
Control of TLR7-mediated type I IFN signaling in pDCs through CXCR4 engagement—A new target for lupus treatment
CXCR4 engagement by amines leads to the control of IFN signaling in pDCs and opens new therapeutic perspectives in Lupus patients.
- 5 July 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 5 (7) , eaav9019
Open AccessControl of TLR7-mediated type I IFN signaling in pDCs through CXCR4 engagement—A new target for lupus treatment
CXCR4 engagement by amines leads to the control of IFN signaling in pDCs and opens new therapeutic perspectives in Lupus patients.